Eluvixtamab

Eluvixtamab (AMG-330) is a bispecific T-cell engager. Eluvixtamab binds to CD33 and CD3 on T cells, thereby promoting T cell-mediated cytotoxicity against CD33+ cells. Eluvixtamab can be used in the research of tumors such as relapsed/refractory acute myeloid leukemia[1].

Product Specifications

CAS Number

[1679391-73-1]

Product Name Alternative

AMG-330

UNSPSC

12352203

Target

CD3; Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/eluvixtamab.html

Purity

97.28

Smiles

[Eluvixtamab]

Molecular Weight

(54.34 kDa)

References & Citations

[1]Ravandi F, et al. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study. Leuk Lymphoma. 2024 Sep;65 (9) :1281-1291.